• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Neoadjuvant Treatment in Locally Advanced Thyroid Carcinoma.局部晚期甲状腺癌的新辅助治疗
J Clin Med. 2024 Sep 27;13(19):5769. doi: 10.3390/jcm13195769.
2
Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma.局部晚期不可切除甲状腺癌患者的新辅助多激酶抑制剂治疗
Front Endocrinol (Lausanne). 2019 Oct 22;10:712. doi: 10.3389/fendo.2019.00712. eCollection 2019.
3
Neoadjuvant tyrosine kinase inhibitor therapy in locally advanced differentiated thyroid cancer: a single centre case series.局部晚期分化型甲状腺癌的新辅助酪氨酸激酶抑制剂治疗:单中心病例系列。
J Laryngol Otol. 2023 Nov;137(11):1237-1243. doi: 10.1017/S0022215123000506. Epub 2023 Mar 22.
4
The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial.安罗替尼在局部晚期甲状腺癌新辅助治疗中的疗效和安全性:一项单臂、Ⅱ期临床研究。
Thyroid. 2021 Dec;31(12):1808-1813. doi: 10.1089/thy.2021.0307. Epub 2021 Nov 29.
5
Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience.局部晚期甲状腺癌的新辅助治疗:初步的拉丁美洲经验。
Thyroid. 2024 Jul;34(7):949-952. doi: 10.1089/thy.2024.0090. Epub 2024 Jun 3.
6
Targeted Oncogene Therapy Before Surgery in Pediatric Patients With Advanced Invasive Thyroid Cancer at Initial Presentation: Is It Time for a Paradigm Shift?术前靶向肿瘤治疗在初诊晚期侵袭性小儿甲状腺癌患者中的应用:是否到了范式转变的时候?
JAMA Otolaryngol Head Neck Surg. 2020 Aug 1;146(8):748-753. doi: 10.1001/jamaoto.2020.1340.
7
Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.斯洛文尼亚局部晚期转移性甲状腺髓样癌患者接受酪氨酸激酶抑制剂诱导治疗的结果。
Adv Ther. 2021 Dec;38(12):5684-5699. doi: 10.1007/s12325-021-01940-2. Epub 2021 Oct 21.
8
Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: A case report.乐伐替尼治疗后局部晚期乳头状甲状腺癌的手术治疗:一例报告
Int J Surg Case Rep. 2017;41:89-92. doi: 10.1016/j.ijscr.2017.10.010. Epub 2017 Oct 14.
9
Effectiveness of preoperative radioactive iodine (131I) therapy for locally advanced papillary thyroid cancer: a case report.术前放射性碘(131I)治疗局部晚期甲状腺乳头状癌的疗效:一例报告
Thyroid. 1998 Dec;8(12):1113-6. doi: 10.1089/thy.1998.8.1113.
10
Overview of resistance to systemic therapy in patients with breast cancer.乳腺癌患者全身治疗耐药概述。
Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1.

引用本文的文献

1
Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer.多激酶和高选择性激酶抑制剂在甲状腺癌患者新辅助治疗中的应用
Explor Target Antitumor Ther. 2025 Feb 13;6:1002291. doi: 10.37349/etat.2025.1002291. eCollection 2025.

本文引用的文献

1
European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management.欧洲内分泌外科学会(ESES)关于晚期甲状腺癌的共识声明:定义与管理
Br J Surg. 2024 Aug 2;111(8). doi: 10.1093/bjs/znae199.
2
Neoadjuvant treatment with lenvatinib and pembrolizumab in a V600E-mutated anaplastic thyroid cancer: a case report.仑伐替尼联合帕博利珠单抗治疗 V600E 突变型甲状腺未分化癌一例报告。
Front Endocrinol (Lausanne). 2024 Jul 9;15:1389294. doi: 10.3389/fendo.2024.1389294. eCollection 2024.
3
CAR-T cell therapy in advanced thyroid cancer: from basic to clinical.嵌合抗原受体 T 细胞疗法治疗晚期甲状腺癌:从基础到临床。
Front Immunol. 2024 Jun 7;15:1411300. doi: 10.3389/fimmu.2024.1411300. eCollection 2024.
4
Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Preliminary Latin American Experience.局部晚期甲状腺癌的新辅助治疗:初步的拉丁美洲经验。
Thyroid. 2024 Jul;34(7):949-952. doi: 10.1089/thy.2024.0090. Epub 2024 Jun 3.
5
Single Institution Experience in the Management of Locally Advanced (pT4) Differentiated Thyroid Carcinomas.单机构治疗局部晚期(pT4)分化型甲状腺癌的经验
Ann Surg Oncol. 2024 Sep;31(9):5515-5524. doi: 10.1245/s10434-024-15356-z. Epub 2024 May 3.
6
Thyroid Cancer: A Review.甲状腺癌:综述。
JAMA. 2024 Feb 6;331(5):425-435. doi: 10.1001/jama.2023.26348.
7
Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial.安罗替尼用于局部晚期或转移性放射性碘难治性分化型甲状腺癌:一项随机、双盲、多中心II期试验。
Clin Cancer Res. 2023 Oct 13;29(20):4047-4056. doi: 10.1158/1078-0432.CCR-22-3406.
8
The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II Study.苏呋替尼联合抗PD-1抗体托瑞帕利单抗在局部晚期分化型甲状腺癌新辅助治疗中的疗效和安全性:一项II期研究
Ann Surg Oncol. 2023 Nov;30(12):7172-7180. doi: 10.1245/s10434-023-14031-z. Epub 2023 Aug 5.
9
Modulation of EZH2 Activity Induces an Antitumoral Effect and Cell Redifferentiation in Anaplastic Thyroid Cancer.EZH2 活性的调节可诱导间变性甲状腺癌的抗肿瘤作用和细胞再分化。
Int J Mol Sci. 2023 Apr 26;24(9):7872. doi: 10.3390/ijms24097872.
10
Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study.BRAF 靶向治疗后手术与 BRAF 突变型间变性甲状腺癌患者生存改善相关:单中心回顾性队列研究。
Thyroid. 2023 Apr;33(4):484-491. doi: 10.1089/thy.2022.0504. Epub 2023 Mar 20.

局部晚期甲状腺癌的新辅助治疗

Neoadjuvant Treatment in Locally Advanced Thyroid Carcinoma.

作者信息

Navas Moreno Víctor, Sebastián Valles Fernando, Lahera Vargas Marcos, Hernández Marín Berta, Carrillo López Elena, Marazuela Mónica, Muñoz de Nova José Luis

机构信息

Department of Endocrinology and Nutrition, Hospital Universitario de La Princesa, 28028 Madrid, Spain.

Instituto de Investigación Sanitaria Princesa (IIS-IP), 28028 Madrid, Spain.

出版信息

J Clin Med. 2024 Sep 27;13(19):5769. doi: 10.3390/jcm13195769.

DOI:10.3390/jcm13195769
PMID:39407830
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11477333/
Abstract

Although the focus in the last decades has been on the overdiagnosis of incidentally detected thyroid carcinomas in early stages, the other extreme of the disease is represented by locally advanced tumors with the invasion of neighboring structures. These are infrequent tumors, but they have a high complexity and a poor prognosis. In the absence of effective therapies allowing preoperative tumor reduction, in order to achieve a more restricted surgery, treatment was limited to aggressive surgery with resection of the aerodigestive tract and major vascular structures or palliative treatment. However, due to the increased knowledge of tumor biology and the results that tyrosine kinase inhibitors have achieved in the treatment of radioactive iodine-refractory tumors, neoadjuvant therapy with a curative intent has emerged as a reality to be taken into account when dealing with these patients. This paper presents a narrative review of the current scientific evidence regarding neoadjuvant treatment in locally advanced thyroid cancer.

摘要

尽管在过去几十年里,重点一直是早期偶然发现的甲状腺癌的过度诊断,但该疾病的另一个极端表现为侵犯邻近结构的局部晚期肿瘤。这些肿瘤并不常见,但具有高度复杂性且预后较差。在缺乏能使肿瘤在术前缩小的有效治疗方法的情况下,为了实现更有限的手术,治疗仅限于切除气道消化道和主要血管结构的根治性手术或姑息治疗。然而,由于对肿瘤生物学的认识不断增加以及酪氨酸激酶抑制剂在放射性碘难治性肿瘤治疗中取得的成果,以治愈为目的的新辅助治疗已成为在处理这些患者时需要考虑的现实。本文对局部晚期甲状腺癌新辅助治疗的当前科学证据进行了叙述性综述。